NEW YORK ( TheStreet) -- CHANGE IN RATINGSAssurant ( AIZ) downgraded at BofA/Merrill from Buy to Neutral, Bank of America/Merrill Lynch said. Company is facing increased regulatory risk. $45 price target. Armstrong World ( AWI) downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call. BB&T ( BBT) downgraded at Guggenheim from Buy to Hold, Guggenheim said. Valuation call, based on a $34 price target. Blackrock ( BLK) downgraded at Morgan Stanley from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $224 price target. Capital One ( COF) upgraded at Guggenheim from Neutral to Buy, Guggenheim said. $67 price target. Recent acquisitions should add to earnings. Cintas ( CTAS) downgraded at Baird from Outperform to Neutral, Robert Baird said. Valuation call, based on a $45 price target. Cloud Peak Energy ( CLD) downgraded to hold at TheStreet Ratings. Edgewater Technology ( EDGW) downgraded to hold at TheStreet Ratings. Hudson City ( HCBK) rated new Buy at Compass Point. Valuation call, based on an $8.50 price target. LinkedIn ( LNKD) upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $135 price target. Estimates also boosted, given higher operating metrics. Allscripts ( MDRX) downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. Performance has lagged since the Eclipsys merger. MicroStrategy ( MSTR) rated new Buy at Think. $160 price target. License business is likely to show accelerated growth over the next couple of years. M&T Bank ( MTB) downgraded at Guggenheim from Buy to Neutral, Guggenheim said. $96 price target. Company is less attractive in an improving economy. Nisource ( NI) upgraded at Keybanc from Hold to Buy, Keybanc said. $26.50 price target. Stock is attractive, based on a sum-of-the-parts valuation. Regions Financial ( RF) upgraded at Guggenheim from Neutral to Buy, Guggenheim said. Valuation call, based on a $9 price target. Royal Gold ( RGLD) upgraded at National Bank Financial to Outperform from Sector Perform, National Bank Financial. $82 price target. Recent sell off overdone. Silicon Laboratories ( SLAB) upgraded at UBS to Buy from Neutral, UBS said. $50 price target. Expect new CEO to raise R&D efficiency. US Silica ( SLCA) rated new Buy at Dahlman. $25 price target. Company is leveraged to growth in the fracture proppant market. Suntrust ( STI) downgraded at Guggenheim from Buy to Neutral, Guggenheim said. Valuation call, based on a $26 price target.
STOCK COMMENTS / EPS CHANGES
Amedisys ( AMED) numbers raised at Jefferies. Shares of AMED now seen reaching $16.50, Jefferies said. Estimates also raised to reflect benefit of agency rationalization efforts. Hold rating.